8-K filed Aug 4, 2026 at 07:40 ET
Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net loss of $4.9M ($3.91/share) in Q2 2025. The company highlighted that topline Phase 2 data for PIKTOR in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 breast cancer trial. The company has $186.4M in cash and securities, providing runway through key milestones. The filing is a routine quarterly update for a clinical-stage biotech with no revenue and no consensus estimates provided for the current quarter, making it neutral with low impact.